Revision of full-year consolidated earnings forecast. Revenue is expected to decrease from the previous forecast of 1,310,000 million yen to 1,165,000 million yen, while core operating income is expected to rise from 140,000 million yen to 196,000 million yen. The Crystallase Chemical segment is treated as a non-continuing business, and overall revenue is expected to decrease, though some segments are anticipated to contribute to profit.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4004","jir_company_name":"Publicly listed company: Resonac Holdings Corporation","jir_importance":"\u2605\u2605\u2605\u2605","jir_publication_date":"2026-08-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4004-20260806-03.pdf","jir_short_summary":"Revision of full-year consolidated earnings forecast. Revenue is expected to decrease from the previous forecast of 1,310,000 million yen to 1,165,000 million yen, while core operating income is expected to rise from 140,000 million yen to 196,000 million yen. The Crystallase Chemical segment is treated as a non-continuing business, and overall revenue is expected to decrease, though some segments are anticipated to contribute to profit.","jir_summary":"### Overview of performance\nIn this release, the full-year consolidated earnings forecast for the fiscal year ending December 2026 is revised downward to revenue of 1,165,000 million yen, while core operating income is expected to increase to 196,000 million yen. Major factors from the previous forecast include the treatment of the Crystallase Chemical segment as a non-continuing business, resulting in revenue decline, and higher profit from increased sales volume in the semiconductor\/electronics materials segment. The impact of discontinuation of consolidation is not included.\n\n### Outlook and implications\nExcluding the impact of non-continuing operations, core indicators are expected to rise. However, due to the treatment change of the Crystallase Chemical segment, total revenue is expected to decrease. External factors such as exchange rates may continue to affect performance, so close attention to future updates is required.","jir_financial_highlights":"Revenue: 1,165,000 (Previous forecast (A) 1,310,000 \u2192 Current forecast (B) 1,165,000 million yen, \u25b3145,000)\nCore operating income: 196,000 (Previous forecast (A) 140,000 \u2192 Current forecast (B) 196,000 million yen, \uff0b56,000)\nNet income for the period: 112,500 (Previous forecast (A) 79,000 \u2192 Current forecast (B) 112,500 million yen, \uff0b33,500)\nNet income attributable to owners of parent: 112,500 (Previous forecast (A) 77,000 \u2192 Current forecast (B) 112,500 million yen, \uff0b35,500)\nBasic earnings per share: 606.32 (Previous forecast (A) 414.99 \u2192 Current forecast (B) 606.32 yen)","jir_category":"","jir_hashtags":"#ResonacHoldings, #EarningsRevision, #SegmentTrends","jir_key_figures":"Revenue: 1,165,000 million yen\nCore operating income: 196,000 million yen\nNet income for the period: 112,500 million yen","jir_meta_title":"\u3010Resonac Holdings\u3011Full-Year Earnings Revision \uff5c Revenue 1,165,000 million yen, Core income 196,000 million yen","jir_meta_description":"Resonac Holdings revises its full-year consolidated earnings forecast for the 2026 fiscal year. Revenue is expected to decrease, but core operating income is set to increase. Summary of the non-continuation effect of Crystallase Chemical and segment-wise trends.","jir_og_title":"\u3010Resonac Holdings\u3011Full-Year Earnings Revision \uff5c Revenue 1,165,000 million yen, Core income 196,000 million yen","jir_og_description":"Resonac Holdings revises its full-year forecast. Detailed discussion of revenue decline factors and segment-specific profitability trends.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7528,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-97465","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n